Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Sees Large Decrease in Short Interest

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) saw a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 16,531 shares, a decrease of 66.2% from the May 31st total of 48,965 shares. Based on an average daily volume of 10,212 shares, the short-interest ratio is currently 1.6 days.

Rocket Pharmaceuticals Trading Down 13.0%

NASDAQ:RCKTW traded down $0.00 on Monday, hitting $0.01. The stock had a trading volume of 17,105 shares, compared to its average volume of 27,838. Rocket Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.08. The firm’s fifty day simple moving average is $0.01 and its two-hundred day simple moving average is $0.02.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.